newsfilter
← Latest News
Business Wire·

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)

U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV)